Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sonic Healthcare Limited (SHL.AX)
AUD21.41
+0.48 (+2.29%)
AU ASX Healthcare Medical - Diagnostics & Research
Address
Grosvenor Place 2000
Sydney, NSW, AU
Sydney, NSW, AU
CEO
James Pacey Newcombe
Website
sonichealthcare.com
IPO
1999-01-03
ISIN AU000000SHL7
Also trades on
Australian Securities Exchange · SHL.AX (AUD)
Other OTC · SKHCF (USD)
Other OTC · SKHHY (USD)
Description
Sonic Healthcare Limited delivers medical diagnostic services to a diverse clientele, including medical professionals, hospitals, public health organizations, and individual patients. The company's services encompass a broad spectrum of laboratory medicine and pathology testing, covering biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal diagnostics, toxicology, and other related functions. Furthermore, Sonic provides extensive radiology services, such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. Its offerings also extend to primary care medical services, featuring general practice clinics, occupational health, specialized skin cancer clinics, after-hours GP services, IT solutions for general practices, and various community-based healthcare programs. Operating internationally, the company has a significant presence in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, and Belgium. Founded in 1934, Sonic Healthcare Limited is headquartered in Sydney, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD21.41
+0.48 (+2.29%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.59
Float Shares
458.20M
Free Float %
92.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.72% | +5.06% | -1.26% | -18.09% | -16.33% | -13.67% | -26.86% | -44.53% | -43.89% | -8.79% | +7,407.69% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
21.41
DCF (Unlevered)
69.30
+223.7%
DCF (Levered)
72.85
+240.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
38% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 7 | -1 |
| Sell | 2 | +1 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
2.51
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+8.0% ★ Q4'25: +26.7% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+0.0% Q4'25: +23.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+4.8% Q4'25: +6.6% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+9.7% ★ Q4'25: +8.3% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%+5.2% Q4'25: +8.5% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.9% Q4'25: +4.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×4.16× Q4'25: 2.08× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2000 actual |
Jun 2001 actual |
Jun 2002 actual |
Jun 2003 actual |
Jun 2004 actual |
Jun 2005 actual |
Jun 2006 actual |
Jun 2007 actual |
Jun 2008 actual |
Jun 2009 actual |
Jun 2010 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 15 Rev. Ana. 12 EPS Ana. |
Jun 2027 15 Rev. Ana. 13 EPS Ana. |
Jun 2028 14 Rev. Ana. 11 EPS Ana. |
Jun 2029 10 Rev. Ana. 7 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 385.72M (-100.0%)
|
621.53M
est: 628.50M (-1.1%)
|
849.26M
est: 764.93M (+11.0%)
|
964.60M
est: 990.36M (-2.6%)
|
1.03B
est: 1.06B (-2.9%)
|
1.36B
est: 1.39B (-2.1%)
|
1.63B
est: 1.68B (-3.0%)
|
1.85B
est: 1.88B (-1.9%)
|
2.33B
est: 2.38B (-2.2%)
|
2.97B
est: 3.06B (-3.1%)
|
2.97B
est: 3.00B (-0.9%)
|
3.08B
est: 3.17B (-2.7%)
|
3.32B
est: 3.37B (-1.4%)
|
3.43B
est: 3.53B (-3.0%)
|
3.85B
est: 3.97B (-3.0%)
|
4.14B
est: 4.17B (-0.7%)
|
4.95B
est: 4.93B (+0.3%)
|
5.05B
est: 5.15B (-1.8%)
|
5.48B
est: 5.52B (-0.8%)
|
6.13B
est: 6.17B (-0.6%)
|
6.56B
est: 6.61B (-0.8%)
|
8.75B
est: 8.95B (-2.2%)
|
9.31B
est: 9.21B (+1.0%)
|
8.14B
est: 8.10B (+0.6%)
|
8.93B
est: 8.86B (+0.8%)
|
9.65B
est: 9.75B (-1.0%)
|
10.95B
10.76B – 11.15B
+12.4% YoY
|
11.33B
10.96B – 11.64B
+3.5% YoY
|
11.80B
11.80B – 11.81B
+4.2% YoY
|
12.23B
11.93B – 12.51B
+3.6% YoY
|
| EBITDA |
56.06M
est: 59.82M (-6.3%)
|
138.21M
est: 35.52M (+289.1%)
|
185.41M
est: 36.15M (+412.9%)
|
209.91M
est: 44.28M (+374.1%)
|
234.61M
est: 44.70M (+424.8%)
|
308.04M
est: 88.87M (+246.6%)
|
359.39M
est: 116.03M (+209.7%)
|
409.50M
est: 233.60M (+75.3%)
|
487.48M
est: 283.77M (+71.8%)
|
436.03M
est: 325.02M (+34.2%)
|
557.84M
est: 158.45M (+252.1%)
|
576.40M
est: 341.36M (+68.9%)
|
626.95M
est: 339.42M (+84.7%)
|
649.40M
est: 355.50M (+82.7%)
|
709.67M
est: 420.20M (+68.9%)
|
698.37M
est: 482.51M (+44.7%)
|
884.53M
est: 475.42M (+86.1%)
|
871.45M
est: 540.54M (+61.2%)
|
951.46M
est: 526.83M (+80.6%)
|
1.08B
est: 615.56M (+75.7%)
|
1.42B
est: 670.25M (+111.5%)
|
2.56B
est: 663.15M (+286.4%)
|
2.83B
est: 681.80M (+315.4%)
|
1.72B
est: 678.63M (+153.6%)
|
1.66B
est: 686.77M (+141.6%)
|
1.24B
est: 2.23B (-44.2%)
|
2.46B
2.42B – 2.51B
+10.4% YoY
|
2.55B
2.46B – 2.61B
+3.5% YoY
|
2.65B
2.65B – 2.65B
+4.2% YoY
|
2.75B
2.68B – 2.81B
+3.6% YoY
|
| EBIT |
-12.21M
est: 70.56M (-117.3%)
|
79.22M
est: 91.41M (-13.3%)
|
99.01M
est: 99.31M (-0.3%)
|
110.47M
est: 128.18M (-13.8%)
|
133.61M
est: 123.65M (+8.1%)
|
190.35M
est: 182.21M (+4.5%)
|
303.29M
est: 235.08M (+29.0%)
|
344.76M
est: 345.95M (-0.3%)
|
405.66M
est: 436.42M (-7.0%)
|
334.74M
est: 521.60M (-35.8%)
|
448.46M
est: 329.34M (+36.2%)
|
461.00M
est: 474.65M (-2.9%)
|
494.64M
est: 490.59M (+0.8%)
|
508.26M
est: 518.69M (-2.0%)
|
575.68M
est: 571.97M (+0.6%)
|
519.17M
est: 616.75M (-15.8%)
|
664.61M
est: 615.53M (+8.0%)
|
643.88M
est: 696.56M (-7.6%)
|
695.43M
est: 688.12M (+1.1%)
|
808.32M
est: 779.47M (+3.7%)
|
811.91M
est: 864.29M (-6.1%)
|
1.92B
est: 941.20M (+104.1%)
|
2.16B
est: 967.67M (+122.9%)
|
1.02B
est: 963.16M (+5.7%)
|
882.00M
est: 974.73M (-9.5%)
|
936.19M
est: 1.53B (-38.9%)
|
1.69B
1.66B – 1.72B
+10.4% YoY
|
1.75B
1.69B – 1.80B
+3.5% YoY
|
1.82B
1.82B – 1.82B
+4.2% YoY
|
1.89B
1.84B – 1.93B
+3.6% YoY
|
| Net Income |
-3.19M
est: 38.35M (-108.3%)
|
52.0K
est: 30.47M (-99.8%)
|
1.55M
est: 31.89M (-95.1%)
|
913.0K
est: 43.76M (-97.9%)
|
-255.0K
est: 43.64M (-100.6%)
|
-11.94M
est: 75.83M (-115.8%)
|
172.03M
est: 93.48M (+84.0%)
|
198.07M
est: 194.01M (+2.1%)
|
245.12M
est: 250.74M (-2.2%)
|
171.36M
est: 315.12M (-45.6%)
|
293.23M
est: 167.85M (+74.7%)
|
294.54M
est: 309.67M (-4.9%)
|
316.00M
est: 313.06M (+0.9%)
|
335.00M
est: 331.19M (+1.2%)
|
384.98M
est: 376.89M (+2.1%)
|
347.70M
est: 412.45M (-15.7%)
|
451.37M
est: 412.18M (+9.5%)
|
427.77M
est: 472.95M (-9.6%)
|
475.61M
est: 457.17M (+4.0%)
|
549.73M
est: 533.08M (+3.1%)
|
527.75M
est: 587.79M (-10.2%)
|
1.32B
est: 611.78M (+115.0%)
|
1.46B
est: 628.99M (+132.2%)
|
684.98M
est: 684.98M (+0.0%)
|
511.09M
est: 511.09M (+0.0%)
|
513.60M
est: 513.60M (+0.0%)
|
605.00M
560.95M – 619.44M
+17.8% YoY
|
670.96M
613.04M – 683.92M
+10.9% YoY
|
735.16M
641.78M – 755.51M
+9.6% YoY
|
741.20M
717.05M – 763.01M
+0.8% YoY
|
| SGA |
—
est: 31.34M (-100.0%)
|
309.37M
est: 56.21M (+450.3%)
|
459.58M
est: 407.36M (+12.8%)
|
515.56M
est: 626.38M (-17.7%)
|
544.38M
est: 578.36M (-5.9%)
|
677.39M
est: 784.12M (-13.6%)
|
908.16M
est: 896.66M (+1.3%)
|
981.73M
est: 1.07B (-8.0%)
|
1.17B
est: 1.35B (-13.3%)
|
1.46B
est: 1.73B (-15.8%)
|
1.48B
est: 1.64B (-10.1%)
|
1.55B
est: 1.80B (-14.0%)
|
1.70B
est: 1.89B (-10.0%)
|
1.89B
est: 2.04B (-7.0%)
|
2.12B
est: 2.31B (-8.4%)
|
2.32B
est: 2.46B (-5.6%)
|
2.75B
est: 2.99B (-8.2%)
|
2.81B
est: 3.13B (-10.3%)
|
3.02B
est: 3.27B (-7.7%)
|
3.20B
est: 3.69B (-13.3%)
|
3.23B
est: 3.92B (-17.7%)
|
3.42B
est: 4.34B (-21.1%)
|
3.89B
est: 4.46B (-12.9%)
|
4.09B
est: 4.44B (-8.0%)
|
4.38B
est: 4.50B (-2.7%)
|
267.56M
est: 3.63B (-92.6%)
|
4.00B
3.93B – 4.08B
+10.4% YoY
|
4.14B
4.01B – 4.25B
+3.5% YoY
|
4.31B
4.31B – 4.32B
+4.2% YoY
|
4.47B
4.36B – 4.57B
+3.6% YoY
|
| EPS |
-0.02
est: 0.14 (-115.8%)
|
0.13
est: 0.14 (-5.6%)
|
0.14
est: 0.20 (-28.9%)
|
0.16
est: 0.16 (-0.4%)
|
0.22
est: 0.21 (+3.0%)
|
0.28
est: 0.29 (-4.4%)
|
0.60
est: 0.62 (-3.1%)
|
0.67
est: 0.67 (-0.4%)
|
0.75
est: 0.75 (-0.3%)
|
0.47
est: 0.85 (-44.6%)
|
0.76
est: 0.78 (-2.1%)
|
0.76
est: 0.77 (-0.7%)
|
0.81
est: 0.81 (+0.2%)
|
0.85
est: 0.84 (+1.0%)
|
0.96
est: 0.99 (-2.6%)
|
0.91
est: 0.93 (-2.4%)
|
1.10
est: 1.04 (+5.7%)
|
1.03
est: 1.07 (-4.1%)
|
1.13
est: 1.11 (+2.1%)
|
1.22
est: 1.18 (+3.8%)
|
1.11
est: 1.08 (+2.5%)
|
2.75
est: 2.82 (-2.4%)
|
3.05
est: 2.94 (+3.8%)
|
1.46
est: 1.52 (-4.3%)
|
1.07
est: 1.01 (+6.4%)
|
1.07
est: 1.10 (-2.5%)
|
1.22
1.17 – 1.29
+11.2% YoY
|
1.34
1.27 – 1.42
+9.6% YoY
|
1.46
1.33 – 1.57
+8.9% YoY
|
1.54
1.49 – 1.59
+5.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.62B
OE per share TTM
5.41
Owner's Yield
27.11%
Maintenance CapEx ratio
12.47%
Maint CapEx / Avg PPE
31.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
374.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
1
-1 vs prev Q
New positions
0
Closed positions
1
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | SEQUENT ASSET MANAGEMENT, LLC | 26.7K +— (+0.0%) | 374.0K +28.2K (+8.2%) | 0.01% +0.000 pp | 0.17% +0.002 pp | AUD22.06 +2.5% | 38 qtrs — |
| 2 | BOSTON COMMON ASSET MANAGEMENT, LLC | — -28.2K (-100.0%) | — -400.4K (-100.0%) | 0.00% -0.006 pp | 0.00% -0.011 pp | AUD— | 10 qtrs SOLD |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
22.3K
Shares Outstanding
494.24M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher David Wilks | Finance Director, Chief Financial Officer & Executive Director | 2M | male |
| Diane Harari | Chief Communications Officer | — | — |
| Evangelos Kotsopoulos | Group Chief Operating Officer | — | male |
| Graham Beal | Chief People Officer | — | — |
| James Pacey Newcombe | MD, CEO & Executive Director | — | — |
| Jess Onus | Chief Sustainability Officer | — | — |
| Leisel Hickey | Chief Procurement Officer | — | — |
| Maki Takken | General Counsel | — | — |
| Peter Joseph | Global Head of Cybersecurity | — | — |
| Peter Savage | Chief Business Officer | — | male |
| Stephen Fairy | Chief Medical Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SHL.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
